| DATE |
CONFERENCE |
TITLE |
AUTHORS |
| May 2020 |
American Association of Immunologists Annual Meeting |
PT101: A Treg selective agonist IL-2 mutein therapy for autoimmunity |
Nathan Higginson-Scott, Kevin L. Otipoby and Jo Viney |
| Mar 2020 |
Keystone T Cell Memory |
Discovery and Characterization of Tissue-Tethered PD-1 Agonist Antibodies |
Bridget Larkin, Lindsay J. Edwards, Daniel C. Rios, Salvatore Alioto, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby |
| Feb 2020 |
JDRF nPOD (Network for Pancreatic Organ Donors with Diabetes) Annual Meeting |
Bifunctional Antibody Therapy for the treatment of Type 1 Diabetes |
Daniel Rios |
| Dec 2019 |
Antibody Engineering and Therapeutics; San Diego, CA |
Development of PD-1 agonist bispecific antibodies for tissue targeted immunomodulation |
Salvatore L. Alioto, Lindsay J. Edwards, Bridget M. Larkin, Angela Boisvert, Jyothsna Visweswaraiah, Joanne L. Viney, Kevin L. Otipoby, Nathan Higginson-Scott |
| Nov 2019 |
JDRF New England Awards Ceremony; Boston, MA |
Tissue-Specific Immunomodulation as a Novel Treatment for T1D |
Daniel Rios |
| Nov 2019 |
The Promise of Interleukin-2 Therapy; Paris, France |
PT101, A Highly Selective IL-2 Mutein for AutoimmunityICMI |
Kevin L. Otipoby, Nathan Higginson-Scott, Jo Viney |
| Sept 2019 |
World Bispecific Summit; Waltham, MA |
De-risking Bispecific Developability with Early Screens in Bispecific Format |
Nathan Higginson-Scott |
| Sept 2019 |
World Bispecific Summit; Waltham, MA |
Developing targeted IL-2 mutein bispecific antibodies for gut localized immune modulation |
Jyothsna Viswesvaraiah, Erik Sampson, Bridget Larkin, Tim Kiprono, Lindsay Edwards, Sal Alioto, Angela Boisvert, Jo Viney, Kevin Otipoby, Nathan Higginson-Scott |
| July 2019 |
Presentation at St. Vincent's Institute of Medical Research; Fitzroy, Australia |
Enforcing Checkpoint Regulation: Tissue Specific PD-1 Agonism as a Novel T1D Therapeutic Approach Developing targeted IL-2 mutein |
Daniel Rios |
| July 2019 |
International Congress of Mucosal Immunology; Brisbane. Australia |
Selective Expansion of Regulatory T cells by IL-2 Muteins as a Potential Treatment for IBD |
Daniel Rios, Erik R. Sampson, Jyothsna Visweswaraiah, Patrick Halvey,Bridget Larkin, Michael J Rowe, Rajeev K. Tyagi, Jing Li, Justin Jacobse, Margret Allaman, Keith T. Wilson, Jeremy A. Goettel, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby |
| June 2019 |
Federation of Clinical Immunology Societies Annual Meeting; Boston, MA |
Localizing Immunomodulators to Mucosal Tissues |
Erik Sampson, Jyothsna Visweswaraiah, Danny Rios, Lindsay Edwards, Purvi Mande, Susmita Borthakur, Bridget Larkin, Tim Kiprono, Michael Rowe, Nathan Higginson-Scott, Kevin Otipoby, Jo Viney |
| June 2019 |
Federation of Clinical Immunology Societies Annual Meeting; Boston, MA |
Discovery and Characterization of PD-1 Agonist Antibodies |
Lindsay J. Edwards, Daniel C. Rios, Salvatore Alioto, Bridget Larkin, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby |
| June 2019 |
Federation of Clinical Immunology Societies Annual Meeting; Boston, MA |
Selective Expansion of Regulatory T cells by IL-2 Muteins |
Erik R. Sampson, Jyothsna Visweswaraiah, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby |
| May 2019 |
Treg Directed Therapies Summit; Boston, MA |
Localized Immunomodulation of Regulatory T cells in the Gut |
Kevin Otipoby |
| Apr 2019 |
Quantitative Systems Pharmacology Summit; Cambridge, MA |
Localized Immunomodulation for Treating Autoimmune Disease |
Nathan Higginson-Scott |
| Jan 2019 |
Host and the Environment in IBD; Taos, NM |
Discovery and Characterization of PD-1 Agonist Antibodies |
Daniel C. Rios, Lindsay Edwards, Salvatore Alioto, Bridget Larkin, Timothy Kiprono, Nathan Higginson-Scott, Joanne L. Viney, Kevin L. Otipoby |
